A longevity biotech co-founded by Coinbase chief Brian Armstrong that pairs partial epigenetic reprogramming with machine learning to restore youthful gene expression.
Facts
- Founded
- Around 2021
- Co-founders
- Brian Armstrong, Blake Byers, Jacob Kimmel
- Headquarters
- South San Francisco, California
- Focus
- Partial epigenetic reprogramming
- Approach
- High-throughput experiments and machine learning
Overview
NewLimit is an American longevity biotechnology company trying to reverse aspects of cellular aging through partial epigenetic reprogramming, the controlled use of gene-regulating factors to reset old cells toward a younger, healthier state without erasing what kind of cell they are. Co-founded around 2021 by the Coinbase chief executive Brian Armstrong, the investor Blake Byers, and the computational biologist Jacob Kimmel, the company combines laboratory reprogramming experiments with large-scale machine learning to search for the specific combinations of factors that rejuvenate a given cell type. Armstrong, best known for building the cryptocurrency exchange Coinbase, has said he wanted to direct part of his wealth toward what he considers a tractable scientific problem, extending healthy human lifespan, and he seeded the company with a large personal commitment before it added outside venture capital. Reported rounds include a Series A of roughly 40 million dollars in 2023 and a Series B of about 130 million dollars in 2025 led by Kleiner Perkins.
The scientific idea
The intellectual foundation of NewLimit is the discovery by Shinya YamanakaPersonShinya YamanakaJapanese stem-cell scientist who discovered induced pluripotent stem cells and shared the 2012 Nobel Prize, laying the foundation for reprogramming-based rejuvenation.Person → that a small set of proteins, the Yamanaka factors, can convert an ordinary adult cell into an induced pluripotent stem cell. Full reprogramming resets a cell's biological ageTermBiological ageAn estimate of organism or tissue state relative to typical aging patterns, usually inferred from biomarkers rather than birthdays.In glossary → but also wipes out its identity, which is unsafe in a living body. NewLimit, like others in the field, pursues partial reprogramming, exposing cells briefly or to carefully chosen factors so that youthful patterns of gene expression return while the cell keeps doing its original job. Restoring these patterns is meant to address the epigenetic alterations counted among the hallmarks of agingArticleHallmarks of AgingA shared framework that organizes aging into interconnected biological processes, giving longevity research a common map of what to measure and target.Read entry →, and progress is judged in part with biomarkers of aging such as epigenetic clocksArticleEpigenetic ClocksDNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.Read entry →, alongside functional tests of whether the rejuvenated cells actually behave like younger ones. NewLimit sits within a wave of well-funded startups pursuing cellular rejuvenation, most prominently Altos LabsCompanyAltos LabsBiotechnology company launched in 2022 with reportedly around three billion dollars to pursue cellular rejuvenation and reverse aspects of aging through epigenetic reprogramming.Company →, and it shares their central bet that much of aging reflects a loss of epigenetic information rather than permanent genetic damage.
Machine learning and cell programs
What most distinguishes NewLimit's stated approach is scale and automation. Rather than testing only the classic four factors, the company screens large libraries of transcription factors in many combinations, measures the effects on gene expression cell by cell, and uses the resulting data to train machine learning models that predict which factor combinations will rejuvenate a target cell. In this respect its work overlaps with the broader field of AI drug discovery, where models are trained to navigate a search space too large to explore by hand. Early programs have concentrated on specific human cell types rather than whole-body treatment; the company has reported work on aged liver cells, or hepatocytes, and on immune cells such as T cells, arguing that restoring youthful function to defined tissues is a more achievable near-term goal. NewLimit has said its reprogramming factors can be delivered using messenger RNA, the same class of technology behind mRNA vaccines, and it publishes much of its scientific reasoning openly, an unusual stance in a competitive sector.
Reception
NewLimit is watched closely both because of Armstrong's visibility and because reprogramming is among the most ambitious ideas in longevity science. Supporters see its data-driven, openly documented method as a disciplined way to tackle a field long dominated by anecdote, and they view competition with Altos LabsCompanyAltos LabsBiotechnology company launched in 2022 with reportedly around three billion dollars to pursue cellular rejuvenation and reverse aspects of aging through epigenetic reprogramming.Company →, Retro BiosciencesCompanyRetro BiosciencesLongevity biotechnology company launched in 2022 and reportedly funded largely by Sam Altman, aiming to add years to human lifespan through reprogramming, autophagy, and plasma work.Company →, and academic laboratories as healthy for the science. The cautions are the same that apply to reprogramming generally, that pushing cells toward a younger state risks tipping them too far, causing loss of identity or cancer, and that it remains unproven that resetting the marks measured by an epigenetic clock genuinely restores youthful function in a living person. As of the mid-2020s NewLimit had not brought a therapy into human trials, and its results, though promising, remained confined to cells and preclinical models. The company frames its work as a long-term effort rather than an imminent cure.